BIOTECHNOLOGY company Silence Therapeutics has appointed Tim Freeborn as FD.
Freeborn qualified as a chartered accountant with Arthur Goddard & Co, specialising in corporate tax. He then spent 12 years as a finance journalist at the Daily Mail before spending two years editing the Penny Shares Guide. He also wrote part-time for Shares Magazine.
In 2004, Freeborn joined Evolution Securities as an analyst, focusing on renewables and alternative energy, before he joined Xcap Securities in 2009, becoming head of research.
“Silence’s area of biotech is moving incredibly quickly. The company could play a big role and I’m delighted to be joining at this time,” he said.
We discuss the Accountancy Age Top 50+50 supported by Sage; growth at Menzies; and the provision of value-added services
A financial controller who defrauded his company by nearly £25,000 has been jailed for 18 months
An Aberdeenshire director has been disqualified for failing to ensure her restaurant company kept adequate books and records
The director of a company set up to market a fuel-saving device has been disqualified for failing to maintain and preserve proper records